A Phase 1, Open-label Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
Latest Information Update: 26 Sep 2022
At a glance
- Drugs Fedratinib (Primary) ; Fluconazole
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 26 Sep 2022 Results assessing effect of fluconazole on the pharmacokinetics of a single dose of fedratinib, published in the Cancer Chemotherapy and Pharmacology
- 17 Nov 2021 Status changed from not yet recruiting to completed.
- 12 Jan 2021 New trial record